Bibliografía del artículo
1. Maisel AS, Krishnaswamy P, Nowak RM, e col. Rapid measurement of B-type natriuretic peptide in emergency of heart failure. N Engl J Med 2002; 347:161-7.
2. Mair J, Hammerer-Lercher A, Puschendorf B. The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin Chem Lab Med 2001; 39:571-88.
3. Rothenburger M, Wichter T, Schmid C, e col. Aminoterminal pro type B natriuretic peptide as a predictive and prognostic marker in patient with chronic heart failure. J Heart Lung Transplant 2004; 23(10):1189-97.
4. Richards AM, Doughty R, Nicholls G, e col. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin. Prognostic utility and prediction of benefit from carvedilol in chronic isquemic dysfunction. JACC 2001; 37(7):1781-7.
5. Hartmann F, Packer M, Coats AJ, e col. NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy. Eur J Heart Fail 2004; 6(3):343-50.
6. Latini R, Masson S, Anand I, e col. Valsartan Heart Failure Trial Investigators. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2002; 106(19):2454-8.
7. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355:1126-30.
8. Hunink MGM, Glasziou PP. Decision making in health and medicine. Integrating the evidence and values. 1st ed. London: Cambridge University Press, 2001.
9. Ho KKL, Pinsky JL, Kannel WB. The epidemiology of heart failure: The Framingham study. J Am Coll Cardiol 1993; 22(Suppl A)6A-13A.
10. Tavares LR, Victer H, Linhares JM, e col. Epidemiologia da insuficiência cardíaca descompensada em Niterói - Projeto EPICA - Niterói. Arq Bras Cardiol 2004; 82(2)121-4.
11. Araújo DV, Tavares LR, Veríssimo R, Mesquita ET, Ferraz MB. Custo da insuficiência cardíaca no Sistema Único de Saúde. Arq Bras Cardiol 2005; 84:422-7.
12. Ribeiro RA, Mello RGB, Melchior R, e col. Custo anual do manejo da cardiopatia isquêmica crônica no Brasil. Arq Bras Cardiol 2005; 85(1):3-8.
13. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971; 285:1441-6.
14. Carlson EB, Reimer KA, Rankin JS, Peter RH, McCormack KM, Alexander LG. Right ventricular subendocardial infarction in a patient with pulmonary hypertension, right ventricular hypertrophy, and normal coronary arteries. Clin Cardiol 1985; 8:499-502.
15. Remes J, Reunanen A, Aromaa A, Pyorala K. Incidence of heart failure in eastern Finland: a population-based surveillance study. Eur Heart J 1992; 13:588-93.
16. Wright SP, Doughty RN, Pearl A, e col. Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial. J Am Coll Cardiol 2003; 42(10):1793-800.
17. Morimoto T, Hayashino Y, Shimbo T, Izumi T, Fukui T. Is B-type natriuretic peptide-guided heart failure management cost-effective? Int J Cardiol 2004; 96(2):177-81.